These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16554120)

  • 1. Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.
    Klein RL; Dayton RD; Henderson KM; Petrucelli L
    Neurosci Lett; 2006 Jun; 401(1-2):130-5. PubMed ID: 16554120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat.
    Klein RL; Dayton RD; Lin WL; Dickson DW
    Neurobiol Dis; 2005 Oct; 20(1):64-73. PubMed ID: 16137567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
    Lu XH; Fleming SM; Meurers B; Ackerson LC; Mortazavi F; Lo V; Hernandez D; Sulzer D; Jackson GR; Maidment NT; Chesselet MF; Yang XW
    J Neurosci; 2009 Feb; 29(7):1962-76. PubMed ID: 19228951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein.
    Menéndez J; Rodríguez-Navarro JA; Solano RM; Casarejos MJ; Rodal I; Guerrero R; Sánchez MP; Avila J; Mena MA; de Yébenes JG
    Hum Mol Genet; 2006 Jul; 15(13):2045-58. PubMed ID: 16698879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Yamada M; Mizuno Y; Mochizuki H
    Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss.
    Wang HQ; Imai Y; Inoue H; Kataoka A; Iita S; Nukina N; Takahashi R
    J Neurochem; 2008 Oct; 107(1):171-85. PubMed ID: 18691389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
    Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
    Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
    Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1.
    Dong Z; Ferger B; Paterna JC; Vogel D; Furler S; Osinde M; Feldon J; Büeler H
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12438-43. PubMed ID: 14530399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of oxidative stress on parkin and other E3 ligases.
    LaVoie MJ; Cortese GP; Ostaszewski BL; Schlossmacher MG
    J Neurochem; 2007 Dec; 103(6):2354-68. PubMed ID: 17883392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.
    Yasuda T; Hayakawa H; Nihira T; Ren YR; Nakata Y; Nagai M; Hattori N; Miyake K; Takada M; Shimada T; Mizuno Y; Mochizuki H
    J Neuropathol Exp Neurol; 2011 Aug; 70(8):686-97. PubMed ID: 21760537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine covalently modifies and functionally inactivates parkin.
    LaVoie MJ; Ostaszewski BL; Weihofen A; Schlossmacher MG; Selkoe DJ
    Nat Med; 2005 Nov; 11(11):1214-21. PubMed ID: 16227987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration.
    Van Rompuy AS; Lobbestael E; Van der Perren A; Van den Haute C; Baekelandt V
    J Neuropathol Exp Neurol; 2014 Feb; 73(2):159-74. PubMed ID: 24423640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity.
    Liu B; Traini R; Killinger B; Schneider B; Moszczynska A
    Exp Neurol; 2013 Sep; 247():359-72. PubMed ID: 23313192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cre-inducible Adeno Associated Virus-mediated Expression of P301L Mutant Tau Causes Motor Deficits and Neuronal Degeneration in the Substantia Nigra.
    You Y; Botros MB; Enoo AAV; Bockmiller A; Herron S; Delpech JC; Ikezu T
    Neuroscience; 2019 Dec; 422():65-74. PubMed ID: 31689387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.
    Jiang H; Ren Y; Zhao J; Feng J
    Hum Mol Genet; 2004 Aug; 13(16):1745-54. PubMed ID: 15198987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.
    Vercammen L; Van der Perren A; Vaudano E; Gijsbers R; Debyser Z; Van den Haute C; Baekelandt V
    Mol Ther; 2006 Nov; 14(5):716-23. PubMed ID: 16914382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
    Hyun DH; Lee M; Halliwell B; Jenner P
    J Neurosci Res; 2005 Oct; 82(2):232-44. PubMed ID: 16130151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.